Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-11-20 00:00:00 ET · period of report 2025-11-18 · accession 0002024096-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | 2025-08-18 | LXEO | Otero Jose Manuel | Chief Technical Off | S - Sale | $9.27 | -721 | 63.5K | -1% | -$6,684 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-18 | S | D | 721 | $9.27 | 63,476 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 47,733 RSUs. |